Analysts’ Weekly Ratings Updates for Eidos Therapeutics (EIDX)

Eidos Therapeutics (NASDAQ: EIDX) recently received a number of ratings updates from brokerages and research firms:

  • 11/19/2019 – Eidos Therapeutics had its price target raised by analysts at Piper Jaffray Companies from $55.00 to $75.00. They now have an “overweight” rating on the stock.
  • 11/18/2019 – Eidos Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $52.00 price target on the stock. According to Zacks, “Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It discovers and develops novel oral therapy for the treatment of diseases caused by transthyretin amyloidosis. Eidos Therapeutics, Inc. is based in San Francisco, United States. “
  • 11/14/2019 – Eidos Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It discovers and develops novel oral therapy for the treatment of diseases caused by transthyretin amyloidosis. Eidos Therapeutics, Inc. is based in San Francisco, United States. “
  • 11/1/2019 – Eidos Therapeutics was downgraded by analysts at Barclays PLC from an “overweight” rating to an “equal weight” rating. They now have a $45.00 price target on the stock, up previously from $37.00.
  • 11/1/2019 – Eidos Therapeutics had its price target raised by analysts at Roth Capital from $51.00 to $57.00. They now have a “buy” rating on the stock.
  • 10/16/2019 – Eidos Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. They now have a $41.00 price target on the stock. According to Zacks, “Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It discovers and develops novel oral therapy for the treatment of diseases caused by transthyretin amyloidosis. Eidos Therapeutics, Inc. is based in San Francisco, United States. “
  • 10/15/2019 – Eidos Therapeutics was given a new $56.00 price target on by analysts at BTIG Research. They now have a “buy” rating on the stock.
  • 10/2/2019 – Eidos Therapeutics was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 10/2/2019 – Eidos Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It discovers and develops novel oral therapy for the treatment of diseases caused by transthyretin amyloidosis. Eidos Therapeutics, Inc. is based in San Francisco, United States. “

NASDAQ:EIDX traded up $2.57 during midday trading on Tuesday, hitting $57.59. 341,300 shares of the stock were exchanged, compared to its average volume of 159,171. Eidos Therapeutics Inc has a one year low of $11.15 and a one year high of $58.84. The company has a market capitalization of $1.75 billion, a price-to-earnings ratio of -30.96 and a beta of -0.94. The business has a 50-day moving average price of $41.29 and a two-hundred day moving average price of $36.31. The company has a current ratio of 17.00, a quick ratio of 17.00 and a debt-to-equity ratio of 0.03.

Eidos Therapeutics (NASDAQ:EIDX) last announced its earnings results on Thursday, October 31st. The company reported $0.18 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.30) by $0.48. The firm had revenue of $26.69 million for the quarter. Sell-side analysts forecast that Eidos Therapeutics Inc will post -1.07 EPS for the current fiscal year.

In related news, insider Uma Sinha sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, September 25th. The stock was sold at an average price of $38.41, for a total transaction of $96,025.00. Also, insider Jonathan C. Fox sold 5,000 shares of the company’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $45.74, for a total value of $228,700.00. In the last three months, insiders have sold 12,500 shares of company stock worth $502,125. 70.10% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of EIDX. Metropolitan Life Insurance Co NY bought a new position in shares of Eidos Therapeutics in the first quarter valued at $143,000. Strs Ohio increased its holdings in shares of Eidos Therapeutics by 457.1% in the second quarter. Strs Ohio now owns 11,700 shares of the company’s stock valued at $363,000 after buying an additional 9,600 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Eidos Therapeutics in the second quarter valued at $125,000. Swiss National Bank bought a new position in shares of Eidos Therapeutics in the second quarter valued at $426,000. Finally, Alps Advisors Inc. bought a new position in shares of Eidos Therapeutics in the second quarter valued at $2,395,000. 32.42% of the stock is currently owned by institutional investors.

Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.

Further Reading: Convertible Shares

Receive News & Ratings for Eidos Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.